KCNK2 (Potassium Two Pore Domain Channel Subfamily K Member 2) encodes the TREK-1 (TWIK-related potassium channel 1) channel, a mechanosensitive two-pore domain potassium channel highly expressed in the brain. TREK-1 is a member of the K2P channel family that regulates background leak currents and neuronal excitability[1]. This gene is critical for understanding neurodegenerative disease mechanisms, particularly in the context of cellular stress responses and excitotoxicity[2].
| Property | Value |
|---|---|
| Gene Symbol | KCNK2 |
| Full Name | Potassium Two Pore Domain Channel Subfamily K Member 2 |
| Chromosomal Location | 1q41 |
| NCBI Gene ID | 5136 |
| OMIM | 607412 |
| Ensembl ID | ENSG00000024048 |
| UniProt ID | O95069 |
KCNK2 encodes the TREK-1 channel, a member of the two-pore domain potassium (K2P) channel family. Unlike voltage-gated potassium channels, K2P channels contribute to the background leak current that maintains the resting membrane potential[1:1]. TREK-1 has several distinctive physiological properties:
The channel functions as a homodimer, with each subunit containing four transmembrane domains and two pore domains (P1 and P2)[6]. This dimeric structure creates the characteristic two-pore architecture that defines the K2P family.
KCNK2 shows high expression in the central nervous system:
In the brain, TREK-1 is strategically positioned to modulate neuronal excitability in response to mechanical and chemical stimuli associated with neurodegeneration[7].
TREK-1 activation mediates neuroprotective responses to ischemic injury. During stroke, mechanical stress on neurons from edema and tissue deformation activates TREK-1 channels, producing protective hyperpolarization that reduces excitotoxic damage[8]. This makes TREK-1 a potential therapeutic target for stroke treatment.
Altered TREK-1 expression and function have been implicated in epilepsy. Seizure activity can alter the mechanical environment of neurons, affecting TREK-1 channel function. Studies have shown that TREK-1 downregulation contributes to hyperexcitability in epileptic tissue[9].
TREK-1 was the first ion channel directly linked to depression pathophysiology. Antidepressant drugs including fluoxetine (Prozac) inhibit TREK-1 channel activity, and TREK-1 knockout mice exhibit antidepressant-like behavior[10]. This link suggests a role for neuronal excitability modulation in mood disorders.
TREK-1 is expressed in sensory neurons and contributes to mechano-sensitive pain pathways. The channel modulates pain threshold perception and represents a target for novel analgesic development[11].
Emerging evidence suggests K2P channels including TREK-1 may be affected in Alzheimer's disease. Amyloid-beta peptide interaction with lipid membranes can alter channel function, potentially contributing to neuronal dysregulation in AD[12].
TREK-1 activity is modulated by multiple intracellular signaling pathways:
TREK-1 activators represent a potential neuroprotective approach for ischemic stroke and traumatic brain injury. Several compounds have been identified that activate TREK-1 channels, though clinical translation remains ongoing[13].
Understanding TREK-1 inhibition by existing antidepressants provides insight into novel antidepressant mechanisms. Selective TREK-1 modulators may offer alternative treatment approaches for depression[10:1].
Given the role in pain processing, TREK-1 modulators could provide analgesia without opioid side effects. Development of selective TREK-1 activators is an active research area[11:1].
While KCNK2 mutations are not a common cause of monogenic neurological disorders, polymorphisms in the gene have been associated with:
Key experimental approaches for studying KCNK2:
Patel AJ, Honore E, Maingret F, et al. A mammalian two pore domain mechano-sensitive SIK-orthologous channel. EMBO J. 1998. ↩︎ ↩︎
Honore E. The neuronal background K2P channels: from basic physiology to disease. Nat Rev Neurosci. 2007. ↩︎
Patel AJ, Lazdunski M, Honore E. Lipid and mechano-sensitivity of two-pore domain K+ channels. EMBO Rep. 2001. ↩︎
Maingret F, Patel AJ, Lesage F, et al. Mechano- or acid stimulation, two interactive modes of activation of the TREK-1 potassium channel. J Biol Chem. 1999. ↩︎
Patel AJ, Honore E. Properties and modulation of mammalian 2P domain K+ channels. Trends Neurosci. 2001. ↩︎
Lesage F, Lazdunski M. Molecular and functional properties of two-pore-domain potassium channels. Am J Physiol Renal Physiol. 2000. ↩︎
Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004. ↩︎
Heurteaux C, Lucas G, Guy N, et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci. 2006. ↩︎
Pang DS, Robelet C, Guglielmetti C, et al. Altered expression of TASK-1 and TASK-3 in rat and human temporal lobe epilepsy. J Neurophysiol. 2009. ↩︎
Luckhart C, Liedtke WB, Ghose S. The role of TREK-1 in depression and antidepressant action. Neuropharmacology. 2021. ↩︎ ↩︎
Alloui A, Zimmermann K, Mamet J, et al. TREK-1, a K+ channel involved in polymodal pain perception. EMBO J. 2006. ↩︎ ↩︎
Berson A, Puri A, Ravid D, et al. Lipid interactions of amyloidogenic proteins. Nat Rev Neurosci. 2022. ↩︎
Lee M. Neuroprotective two-pore domain potassium channels. Adv Exp Med Biol. 2020. ↩︎